drugset / Trial / NCT00249171

A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients

NCT00249171

Phase 4 Completed 226 enrolled Janssen Pharmaceutica N.V., Belgium
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for emergency treatment of patients with schizophrenia.

Timeline

Start
2001-06
Primary completion
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 2 mg Oral

Indications